Financial News

Financial Report: Bristol-Myers Squibb

Opdivo, Eliquis, and Hep C franchise drives growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb   1Q Revenues: $4.4 Billion (+9%) 1Q Earnings: $1.2 billion (flat) Comments: Opdivo sales were $704 million in the quarter. Sprycel sales were $407 million, up 9%. Yervoy sales were down 19% to $263 million. Eliquis sales were $734 million in the quarter. Orencia sales were up 19% to $475 million. Revenues include the impact of the transfer of Erbitux and Abilify rights to ImClone and Otsuka, respectively. Hepatitis C Franchise sales were up 62% to $427 million. Reya...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters